Table 1.
Previous brain SNCA expression studies.
| Study | Method | Brain Region | #Samples (PD/C) | PMI, hours (range)1 | Expression in PD compared to controls | SNCA Transcript |
|---|---|---|---|---|---|---|
| Neystat et al. (1999) [7] | Ribonuclease protection assay | Substantia nigra | 15 (9/6) | 11.55 (4–18) 10.62 (3.5–17) |
Decreased, both transcripts |
NM_000345.2 NM_007308.1 |
| Frontal cortex | 15 (9/6) | 11.55 (4–18) 10.62 (3.5–17) |
No significant difference | |||
| Kingsbury et al. (2004) [9] | Semiquantitative in situ | Substantia nigra | 11 (7/4) | 23.2 (9.3–56) 33.0 (22–53) |
Decreased | NM_000345.2 |
| Hybridization | Frontal cortex | 12 (8/4) | 24.4 (10.6–40) 33.0 (22–53) |
Decreased | ||
| Temporal cortex | 12 (8/4) | 24.4 (10.6–40) 33.0 (22–53) |
No significant difference | |||
| Chiba-Falek et al. (2006) [11] | Real-time PCR | Mid-brain | 14 (7/7) | 16.93 (2.00–22.08) 18.62 (14–24) |
Increased | NM_000345.2 |
| Frontal cortex | 7 (4/3) | 14 (2–20) 24.66 (22–28) |
No significant difference | |||
| Fuchs et al. (2008) [13] | Real-time PCR | Substantia nigra | 22 (8/14) | All: 25 (N/A) | No significant difference | NM_000345.2 |
| Cingulate gyrus | 32 (13/19) | All: 22 (N/A) | No significant difference | |||
| Cerebellum | 10 (5/5) | All: 15 (N/A) | Decreased | |||
| Beyer et al. (2011) [14] | Real-time PCR | Caudate nucleus | 21 (7/14) | 6.03 (3.5–7.0) 7.40 (3.5–13.0) |
No significant difference | NM_007308.1 |
| Pons | 21 (7/14) | 6.03 (3.5–7.0) 7.40 (3.5–13.0) |
No significant difference | |||
| Temporal cortex | 21 (7/14) | 6.03 (3.5–7.0) 7.40 (3.5–13.0) |
No significant difference |
C: Control; PD: Parkinson disease.
NM_000345.2 =140 amino acid isoform; NM_007308.1 =112 amino acid isoform.
1The postmortem interval mean and range data for PD samples are on the first line and those for control samples are on the second line. The Fuchs et al. study (2008) only had aggregate mean postmortem interval data available.